Latest Period
Q4 2025
Security Snapshot
Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) Institutional Ownership
CUSIP: 03168L105
13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026
Institutions Reporting
276
Shares (Excl. Options)
154,611,607
Price
$12.60
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Class A Common Stock, par value $0.01
- Symbol
- AMRX on Nasdaq
- Shares outstanding
- 313,041,907
- Price per share
- $12.35
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 154,611,607
- Total reported value
- $1,947,866,237
- % of total 13F portfolios
- 0%
- Share change
- +3,322,377
- Value change
- +$47,523,611
- Number of holders
- 276
- Price from insider filings
- $12.35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AMRX - Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 is tracked under CUSIP 03168L105.
- 276 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 276 to 80 between Q4 2025 and Q1 2026.
- Reported value moved from $1,947,866,237 to $149,491,922.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 276 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03168L105?
CUSIP 03168L105 identifies AMRX - Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03168L105:
Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Patel Tushar Bhikhubhai | 16% | $363,365,003 | 48,578,209 | Patel Tushar Bhikhubhai | 14 Mar 2025 | |||
| Patel Chintu | 8.2% | $259,359,420 | 25,910,032 | Patel Chintu | 03 Oct 2025 | |||
| Patel Chirag K. | 7.1% | $179,439,606 | 22,180,421 | Patel Chirag K. | 06 Aug 2025 | |||
| Mahesh Akram | 6.6% | $153,779,517 | 20,558,759 | Akram Mahesh | 31 Mar 2025 | |||
| Patel Dipan | 5.4% | -28% | $244,942,771 | -$100,339,323 | 16,904,263 | -29% | Patel Dipan | 31 Dec 2025 |
| VANGUARD GROUP INC | 5% | $117,905,198 | 15,762,727 | The Vanguard Group | 31 Mar 2025 |
As of 31 Dec 2025, 276 institutional investors reported holding 154,611,607 shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX). This represents 49% of the company’s total 313,041,907 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 5.7% | 17,907,815 | -0.26% | 0% | $225,638,469 |
| BlackRock, Inc. | 4.6% | 14,298,520 | +1.6% | 0% | $180,161,353 |
| Rubric Capital Management LP | 3.9% | 12,334,941 | 0% | 1.9% | $155,420,257 |
| TPG GP A, LLC | 3.9% | 12,328,767 | 0% | 5.8% | $155,342,464 |
| CITADEL ADVISORS LLC | 2% | 6,175,737 | +7.8% | 0.05% | $77,814,286 |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 5,609,040 | +3.3% | 0.01% | $70,680,550 |
| MORGAN STANLEY | 1.5% | 4,818,099 | +38% | 0% | $60,708,057 |
| STATE STREET CORP | 1.3% | 4,110,410 | +3.4% | 0% | $51,791,166 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 3,986,554 | -1.2% | 0% | $50,239,137 |
| Assenagon Asset Management S.A. | 1.2% | 3,761,739 | +75% | 0.07% | $47,397,911 |
| NEUBERGER BERMAN GROUP LLC | 1.2% | 3,655,391 | -1.6% | 0.03% | $46,098,068 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 3,360,198 | +0.82% | 0.03% | $42,338,495 |
| Nuveen, LLC | 1% | 3,221,721 | -0.11% | 0.01% | $40,593,684 |
| D. E. Shaw & Co., Inc. | 0.85% | 2,661,854 | +70% | 0.03% | $33,539,360 |
| GOLDMAN SACHS GROUP INC | 0.82% | 2,581,075 | +4.9% | 0% | $32,521,545 |
| Nantahala Capital Management, LLC | 0.78% | 2,447,516 | -42% | 1.8% | $30,838,702 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.69% | 2,144,471 | +3% | 0% | $27,020,329 |
| ACADIAN ASSET MANAGEMENT LLC | 0.65% | 2,021,171 | -22% | 0.04% | $25,455,000 |
| Invesco Ltd. | 0.56% | 1,750,718 | +3.9% | 0% | $22,059,048 |
| BlackBarn Capital Partners LP | 0.5% | 1,570,000 | -28% | 7.1% | $19,782,000 |
| NORTHERN TRUST CORP | 0.49% | 1,546,347 | -5% | 0% | $19,483,972 |
| Allspring Global Investments Holdings, LLC | 0.47% | 1,480,172 | +30% | 0.03% | $18,738,978 |
| PFM Health Sciences, LP | 0.47% | 1,465,480 | +312% | 1.9% | $18,465,048 |
| Westshore Wealth, LLC | 0.44% | 1,381,910 | 0% | 5.8% | $17,412,066 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.42% | 1,326,540 | +3.7% | 0.02% | $16,714,404 |
Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 12,066,944 | $149,491,922 | +$3,427,212 | $12.43 | 80 |
| 2025 Q4 | 154,611,607 | $1,947,866,237 | +$47,523,611 | $12.60 | 276 |
| 2025 Q3 | 150,638,837 | $1,508,259,054 | +$80,688,644 | $10.01 | 243 |
| 2025 Q2 | 141,656,835 | $1,146,033,099 | +$54,531,142 | $8.09 | 237 |
| 2025 Q1 | 134,631,456 | $1,128,246,067 | +$84,513,755 | $8.38 | 232 |
| 2024 Q4 | 125,924,024 | $997,296,789 | -$136,424,861 | $7.92 | 194 |
| 2024 Q3 | 142,604,811 | $1,186,537,394 | +$32,304,784 | $8.32 | 180 |
| 2024 Q2 | 138,637,695 | $880,361,225 | +$192,128,358 | $6.35 | 179 |
| 2024 Q1 | 108,100,411 | $655,086,509 | -$6,545,489 | $6.06 | 173 |
| 2023 Q4 | 109,241,884 | $663,112,026 | +$52,701,039 | $6.07 | 151 |
| 2023 Q3 | 101,896,343 | $430,042,448 | +$19,693,333 | $4.22 | 141 |
| 2023 Q2 | 97,368,877 | $301,754,419 | +$4,221,215 | $3.10 | 122 |
| 2023 Q1 | 96,883,833 | $134,657,443 | -$8,205,387 | $1.39 | 142 |
| 2022 Q4 | 101,876,885 | $202,739,453 | +$4,463,674 | $1.99 | 155 |
| 2022 Q3 | 99,522,767 | $201,053,119 | -$1,681,376 | $2.02 | 144 |
| 2022 Q2 | 99,362,374 | $315,991,849 | -$2,095,558 | $3.18 | 140 |
| 2022 Q1 | 100,125,536 | $417,146,539 | -$2,779,055 | $4.17 | 154 |
| 2021 Q4 | 100,743,592 | $481,044,810 | -$750,941 | $4.79 | 148 |
| 2021 Q3 | 100,372,906 | $535,260,080 | +$2,515,423 | $5.34 | 150 |
| 2021 Q2 | 99,933,342 | $511,565,477 | -$13,076,955 | $5.12 | 153 |
| 2021 Q1 | 101,580,612 | $683,525,934 | +$24,752,974 | $6.73 | 155 |
| 2020 Q4 | 99,489,363 | $454,601,386 | -$9,010,325 | $4.57 | 128 |
| 2020 Q3 | 101,459,246 | $393,634,017 | -$1,370,007 | $3.88 | 133 |
| 2020 Q2 | 101,691,059 | $484,034,077 | +$16,566,905 | $4.76 | 131 |
| 2020 Q1 | 98,300,162 | $342,039,040 | -$17,271,636 | $3.48 | 117 |
| 2019 Q4 | 101,152,211 | $487,526,241 | -$9,606,036 | $4.82 | 116 |
| 2019 Q3 | 108,293,336 | $314,077,694 | -$45,957,076 | $2.90 | 111 |
| 2019 Q2 | 105,380,317 | $755,561,286 | -$88,067,679 | $7.17 | 116 |
| 2019 Q1 | 109,021,244 | $1,544,805,998 | -$98,023,386 | $14.17 | 150 |
| 2018 Q4 | 116,187,735 | $1,572,087,804 | +$89,696,977 | $13.53 | 157 |
| 2018 Q3 | 108,476,937 | $2,407,193,089 | +$282,716,887 | $22.19 | 162 |
| 2018 Q2 | 97,469,656 | $1,599,487,071 | +$1,599,409,043 | $16.41 | 163 |